MitochondrialLimited ResearchResearch Only

MOTS-c

Mitochondrial ORF of 12S rRNA type-c · AMPK activation via AICAR-independent pathway; modulation of ETAR (endothelin A receptor); improves mitochondrial energy coupling; translocates to nucleus to regulate stress response gene expression

Not medical advice. For educational and research reference only.

Typical Dose

5–10 mg weekly (research protocols)

Route

Injectable

Cycle

Protocol-dependent

Storage

2–8°C Refrigerated

What is MOTS-c?

MOTS-c is a 16-amino acid mitochondria-derived peptide (MDP) encoded within the 12S rRNA region of the mitochondrial genome — one of only a few proteins known to be encoded by mitochondrial DNA. Early human studies and animal research show it activates AMPK signaling, improves insulin sensitivity, enhances exercise capacity, and reduces age-related metabolic decline. Research only.

Mechanism of Action

AMPK activation via AICAR-independent pathway; modulation of ETAR (endothelin A receptor); improves mitochondrial energy coupling; translocates to nucleus to regulate stress response gene expression

Target: AMPK, ETAR (endothelin A receptor), mitochondrial genome

Research Indications

Energy MetabolismEffective

Research supports improvements in mitochondrial bioenergetics and ATP production

Metabolic HealthEffective

May improve insulin sensitivity and glucose metabolism

Longevity MarkersModerate

Early research suggests potential effects on cellular aging markers

Research Protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalDoseFrequencyRoute
Starting DoseLow dosePer protocolVaries
Standard DoseTitratedPer protocolVaries

Peptide & Drug Interactions

Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.

Consult prescriber before combining with any medicationCaution
BPC-157Compatible
NAD+Compatible
Vitamin DCompatible

How to Reconstitute & Inject

Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.

  1. 1

    Remove MOTS-c vial from refrigeration and allow to reach room temperature (15–20 minutes)

  2. 2

    Clean vial top with alcohol swab and allow to air dry completely

  3. 3

    Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)

  4. 4

    Inject BAC water slowly down the side of the vial — do not aim directly at the powder

  5. 5

    Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide

  6. 6

    Allow 2–3 minutes for full dissolution — solution should be clear and colorless

  7. 7

    Draw calculated dose into an insulin syringe for subcutaneous injection

  8. 8

    Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy

  9. 9

    Store reconstituted solution refrigerated (2–8°C) and use within 28 days

What to Expect

Week 1–2

Initial effects and adaptation period. Monitor for any adverse reactions.

Week 2–4

Primary effects begin to manifest. Adjust dosing as recommended by your provider.

Week 4–8

Main therapeutic effects should be established. Assess progress with your provider.

Week 8+

Evaluate results and determine continuation, cycling, or dose adjustments.

Side Effects & Safety

  • Injection site reactions (redness, bruising, mild pain)
  • Potential for allergic reaction — discontinue if rash or hives occur
  • Individual reactions vary — start at the lowest dose and monitor carefully
  • Consult your healthcare provider before use and report any unusual symptoms

FDA Status & Regulatory Info

Research Only

MOTS-c is a 16-amino acid mitochondria-derived peptide (MDP) encoded within the 12S rRNA region of the mitochondrial genome — one of only a few proteins known to be encoded by mitochondrial DNA. Early human studies and animal research show it activates AMPK signaling, improves insulin sensitivity, enhances exercise capacity, and reduces age-related metabolic decline. Research only.

Rx Required: No
503A Ban: No
Telehealth: Available
Full FDA Status Tracker

Frequently Asked Questions

Research References

External links for education only. We do not control third-party content.

Community-reported data

The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.

Community Intelligence

What 110 users report

110 community reports

Positive 17% · Neutral 2% · Negative 81%

Most reported benefits

Appetite
229
Energy
43

Most reported side effects

Injection site irritation
191

Dose distribution

Median: 2000+ mcg · Most common: 2000+ mcg

0–25
4
25–50
0
50–100
0
100–200
1
200–400
8
400–600
10
600–1000
8
1000–2000
41
2000+
157

How repeat users are trending

Among repeat reporters, 58% said they felt similar to their last entry, 29% more positive, and 13% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 43 days · Based on 45 repeat reporters

Share Your Experience

Rate MOTS-c in the PeptIQ app and help the community make informed decisions.

Research purposes only

This page is for educational reference. It is not medical or legal advice. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.